[
  {
    "ts": null,
    "headline": "Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee",
    "summary": "Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.",
    "url": "https://finnhub.io/api/news?id=303b5ffda98d091833cda4518ed68b709c9b7ee68ad5481c0cbe374568362820",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764180201,
      "headline": "Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee",
      "id": 137622183,
      "image": "https://image.cnbcfm.com/api/v1/image/108232828-17641974871764197483-42711632075-1080pnbcnews.jpg?v=1764197486&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.",
      "url": "https://finnhub.io/api/news?id=303b5ffda98d091833cda4518ed68b709c9b7ee68ad5481c0cbe374568362820"
    }
  },
  {
    "ts": null,
    "headline": "CMS Slashes Prices Of 15 Major Drugs - Here's Why Pharma Valuations Won't Suffer",
    "summary": "Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience supports a strong outlook. Click for more.",
    "url": "https://finnhub.io/api/news?id=1f6a4babd9bee8ff46ea9bfd57aa2d2c9e4fb232cd4ea10363ae33b37483d4b4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764176336,
      "headline": "CMS Slashes Prices Of 15 Major Drugs - Here's Why Pharma Valuations Won't Suffer",
      "id": 137615519,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1407294139/image_1407294139.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience supports a strong outlook. Click for more.",
      "url": "https://finnhub.io/api/news?id=1f6a4babd9bee8ff46ea9bfd57aa2d2c9e4fb232cd4ea10363ae33b37483d4b4"
    }
  },
  {
    "ts": null,
    "headline": "Centers for Medicare & Medicaid Services Unveils $12 Billion Net Savings From Reduction in Drug Prices",
    "summary": "The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,",
    "url": "https://finnhub.io/api/news?id=ed453e3d99118aaec5caa763ba61f4f17ea380d03972a2844140b4163ff336ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764151222,
      "headline": "Centers for Medicare & Medicaid Services Unveils $12 Billion Net Savings From Reduction in Drug Prices",
      "id": 137611270,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,",
      "url": "https://finnhub.io/api/news?id=ed453e3d99118aaec5caa763ba61f4f17ea380d03972a2844140b4163ff336ee"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog NVIDIA, AT&T and Amgen",
    "summary": "NVIDIA, AT&T, and Amgen outperform peers as AI growth, 5G expansion, and strong drug sales drive investor optimism.",
    "url": "https://finnhub.io/api/news?id=e17a2211e8cde6bc579e110f2ef8a56763d96409d9c868ac10e97044983e0fb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764140520,
      "headline": "The Zacks Analyst Blog NVIDIA, AT&T and Amgen",
      "id": 137611389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "NVIDIA, AT&T, and Amgen outperform peers as AI growth, 5G expansion, and strong drug sales drive investor optimism.",
      "url": "https://finnhub.io/api/news?id=e17a2211e8cde6bc579e110f2ef8a56763d96409d9c868ac10e97044983e0fb9"
    }
  },
  {
    "ts": null,
    "headline": "IMDELLTRA's FDA Approval and Guideline Upgrade Could Be a Game Changer for Amgen (AMGN)",
    "summary": "Amgen recently announced that the FDA granted full approval to IMDELLTRA (tarlatamab-dlle) for adults with extensive stage small cell lung cancer (ES-SCLC) who have progressed after platinum-based chemotherapy, and the National Comprehensive Cancer Network updated its guidelines to list Tarlatamab as the only Category 1 preferred treatment option for this patient group. This development follows robust results from a global Phase 3 trial indicating IMDELLTRA extended median overall survival...",
    "url": "https://finnhub.io/api/news?id=fa4439dd020ebbdea06a4e2cdd65fabfda6b08fae2ea8548c5b6a88a885de0a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764116581,
      "headline": "IMDELLTRA's FDA Approval and Guideline Upgrade Could Be a Game Changer for Amgen (AMGN)",
      "id": 137611397,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen recently announced that the FDA granted full approval to IMDELLTRA (tarlatamab-dlle) for adults with extensive stage small cell lung cancer (ES-SCLC) who have progressed after platinum-based chemotherapy, and the National Comprehensive Cancer Network updated its guidelines to list Tarlatamab as the only Category 1 preferred treatment option for this patient group. This development follows robust results from a global Phase 3 trial indicating IMDELLTRA extended median overall survival...",
      "url": "https://finnhub.io/api/news?id=fa4439dd020ebbdea06a4e2cdd65fabfda6b08fae2ea8548c5b6a88a885de0a6"
    }
  }
]